2014 – Mar – iMedNet Partner Oncotherapeutics_FINAL semantic database my cloud . who is

Continue Reading

James R. Berenson1, 2, 3, Ori Yellin1, Robert Dichmann4, Dipti Patel- Donnelly5, Ralph V. Boccia6, James D. Hilger1, Youram Nassir7, Regina A. Swift2 and Robert Vescio8 1Oncotherapeutics, Los Angeles, CA, 2James R. Berenson, MD, Inc., Los Angeles, CA, 3Institute for Myeloma and Bone Cancer Research, Los Angeles, CA, 4Central Coast Medical Oncology, Santa Maria, CA, […]

Continue Reading

Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trials for cancer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in San Diego, California on December 10-13 , 2011. The title of the poster is: Bendamustine Combined with Bortezomib […]

Continue Reading

Abstract Purpose: This open-label, phase I dose-escalation study assessed the safety, tolerability, and initial efficacy of Samariam 153 (153Sm)-lexidronam/bortezomib combination therapy for patients with relapsed/refractory multiple myeloma. Experimental Design: Patients were enrolled in six cohorts and given bortezomib (1.0 or 1.3 mg/m2) on days 1, 4, 8, and 11 and 153Sm-lexidronam (0.25, 0.5, or 1.0 […]

Continue Reading